Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com.
Company Details
- Employees
- 92
- Founded
- -
- Address
- United States, United States,united States
- Phone
- +1 (512) 961-1891
- in****@****rma.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- savarapharma.com
- Keywords
- biotech, biopharma, pulmonary, dry-powder, dpi, therapeutics, lung, respiratory, aerosol, inhaler, drug delivery, rare disease.
- HQ
- United States
Savara Inc. Questions
Savara Inc.'s helpline number is +1 (512) 961-1891
Savara Inc.'s website is savarapharma.com
Savara Inc.'s LinkedIn profile is https://www.linkedin.com/company/savara-pharmaceuticals
Savara Inc. has
92 employees.
View email and phone details for 92
employees at Savara Inc..
Savara Inc.'s industry is
Pharmaceutical Manufacturing
Savara Inc.'s top competitors are
Spyre Therapeutics,
Crinetics Pharmaceuticals,
Ptc Therapeutics, Inc.,
Lumos Pharma,
Lenz Therapeutics,
Cytokinetics,
Soleno Therapeutics, Inc.,
Scholar Rock,
Viridian Therapeutics, Inc.,
Aeglea Biotherapeutics.
Savara Inc.'s support email address is info@savarapharma.com
Savara Inc.'s categories are Pharmaceutical Manufacturing
Savara Inc.'s founding year is 2007
